| Reference | 1: Owusu-Boateng I, Anto F. Intermittent preventive treatment of malaria in
pregnancy: a cross-sectional survey to assess uptake of the new
sulfadoxine-pyrimethamine five dose policy in Ghana. Malar J. 2017 Aug
10;16(1):323. doi: 10.1186/s12936-017-1969-7. PubMed PMID: 28797296; PubMed
Central PMCID: PMC5553599.
<br>
2: Chhonker YS, Bhosale VV, Sonkar SK, Chandasana H, Kumar D, Vaish S, Choudhary
SC, Bhadhuria S, Sharma S, Singh RK, Jain GK, Vaish AK, Gaur SPS, Bhatta RS.
Assessment of Clinical Pharmacokinetic Drug-Drug Interaction of Antimalarial
Drugs α/β-Arteether and Sulfadoxine-Pyrimethamine. Antimicrob Agents Chemother.
2017 Aug 24;61(9). pii: e02177-16. doi: 10.1128/AAC.02177-16. Print 2017 Sep.
PubMed PMID: 28674061; PubMed Central PMCID: PMC5571326.
<br>
3: Bourée P. Paludisme : artésunate et sulfadoxine-pyriméthamine versus
artémether-luméfantrine. Med Sante Trop. 2017 Jun 1;27(2):144. doi:
10.1684/mst.2017.0669. PubMed PMID: 28655671.
<br>
4: de Kock M, Tarning J, Workman L, Nyunt MM, Adam I, Barnes KI, Denti P.
Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive
Treatment of Malaria During Pregnancy and After Delivery. CPT Pharmacometrics
Syst Pharmacol. 2017 Jul;6(7):430-438. doi: 10.1002/psp4.12181. Epub 2017 Jun 9.
PubMed PMID: 28597978; PubMed Central PMCID: PMC5529735.
<br>
5: Ikuoyogie K, Ogefere HO, Omoregie R. Prevalence and Risk Factors for
Sulfadoxine Antibody Among Patients Undergoing Treatment for Malaria in Benin
City, Nigeria. Oman Med J. 2017 May;32(3):207-213. doi: 10.5001/omj.2017.39.
PubMed PMID: 28584601; PubMed Central PMCID: PMC5447788.
<br>
6: Ngondi JM, Ishengoma DS, Doctor SM, Thwai KL, Keeler C, Mkude S, Munishi OM,
Willilo RA, Lalji S, Kaspar N, Kitojo C, Paxton LA, Hathaway NJ, Bailey JA,
Juliano JJ, Meshnick SR, Gutman J. Surveillance for sulfadoxine-pyrimethamine
resistant malaria parasites in the Lake and Southern Zones, Tanzania, using
pooling and next-generation sequencing. Malar J. 2017 Jun 5;16(1):236. doi:
10.1186/s12936-017-1886-9. PubMed PMID: 28583119; PubMed Central PMCID:
PMC5460401.
<br>
7: Ayubu MB, Kidima WB. Monitoring Compliance and Acceptability of Intermittent
Preventive Treatment of Malaria Using Sulfadoxine Pyrimethamine after Ten Years
of Implementation in Tanzania. Malar Res Treat. 2017;2017:9761289. doi:
10.1155/2017/9761289. Epub 2017 Mar 30. PubMed PMID: 28465859; PubMed Central
PMCID: PMC5390590.
<br>
8: Ruizendaal E, Tahita MC, Geskus RB, Versteeg I, Scott S, d/’Alessandro U, Lompo
P, Derra K, Traore-Coulibaly M, de Jong MD, Schallig HDFH, Tinto H, Mens PF.
Increase in the prevalence of mutations associated with sulfadoxine-pyrimethamine
resistance in Plasmodium falciparum isolates collected from early to late
pregnancy in Nanoro, Burkina Faso. Malar J. 2017 Apr 28;16(1):179. doi:
10.1186/s12936-017-1831-y. PubMed PMID: 28454537; PubMed Central PMCID:
PMC5410088.
<br>
9: Chico RM, Chaponda EB, Ariti C, Chandramohan D. Sulfadoxine-Pyrimethamine
Exhibits Dose-Response Protection Against Adverse Birth Outcomes Related to
Malaria and Sexually Transmitted and Reproductive Tract Infections. Clin Infect
Dis. 2017 Apr 15;64(8):1043-1051. doi: 10.1093/cid/cix026. PubMed PMID: 28329383;
PubMed Central PMCID: PMC5399940.
<br>
10: Salman S, Baiwog F, Page-Sharp M, Griffin S, Karunajeewa HA, Mueller I,
Rogerson SJ, Siba PM, Ilett KF, Davis TME. Optimal Antimalarial Dose Regimens for
Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on
Population Pharmacokinetic Modeling. Antimicrob Agents Chemother. 2017 Apr
24;61(5). pii: e02291-16. doi: 10.1128/AAC.02291-16. Print 2017 May. PubMed PMID:
28242669; PubMed Central PMCID: PMC5404578.
|
